Basic | |
---|---|
Market Cap | $3.75M |
Price | $2.08 |
52 Week Range | 0.8-10.56 |
Beta | 0.671 |
Margins | |
Gross Profit Margin | 0.00% |
Operating Profit Margin | 0.00% |
Net Profit Margin | 0.00% |
Valuation (TTM) | |
P/E Ratio | -0.47 |
Price to Sales Ratio | 0.00 |
Price to Book Ratio | 0.84 |
PEG Ratio | 0.00 |
Medical - Devices
Healthcare
Mr. Jeffrey Frelick
2
2021-10-13
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
781 552 4452
2 Burlington Woods Drive, Burlington, MA, 01803, US
0001419554